HC Wainwright Reaffirms “Buy” Rating for Prelude Therapeutics (NASDAQ:PRLD)

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright‘s price target suggests a potential upside of 145.40% from the stock’s current price.

A number of other brokerages have also issued reports on PRLD. Wall Street Zen lowered shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th. Citigroup reiterated a “market outperform” rating on shares of Prelude Therapeutics in a research note on Wednesday, October 14th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Prelude Therapeutics in a report on Thursday, September 17th. They set an “overweight” rating and a $12.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Read Our Latest Analysis on Prelude Therapeutics

Prelude Therapeutics Stock Down 1.2%

PRLD opened at $3.26 on Wednesday. The company has a market cap of $260.15 million, a P/E ratio of -5.53 and a beta of 1.22. The firm’s 50-day moving average price is $3.86 and its 200-day moving average price is $4.10. Prelude Therapeutics has a 52-week low of $1.29 and a 52-week high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13). The company had revenue of $5.65 million for the quarter, compared to the consensus estimate of $29.00 million. On average, research analysts anticipate that Prelude Therapeutics will post -0.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PRLD. Polymer Capital Management US LLC purchased a new position in Prelude Therapeutics during the 3rd quarter worth approximately $55,000. Spark Investment Management LLC acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at approximately $56,000. GSA Capital Partners LLP acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at approximately $68,000. Hsbc Holdings PLC acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at approximately $74,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Prelude Therapeutics in the 1st quarter valued at $120,000. 79.72% of the stock is currently owned by hedge funds and other institutional investors.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Further Reading

Analyst Recommendations for Prelude Therapeutics (NASDAQ:PRLD)

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.